Urology Medical News about BPH

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prostatic-specific Antigen Velocity After Holmium Laser Enucleation of the Prostate: Possible Predictor for the Assessment of Treatment Effect Durability for Benign Prostatic Hyperplasia and Detection of Malignancy
Urology, 09/30/09

Elmansy HM et al. – HoLEP results in a significant reduction in PSA that remained at lower levels during follow–up, suggesting that the glandular size reduction after HoLEP is durable. Monitoring of PSAV is important in long–term follow–up of patients for prostatic carcinoma detection after prostatic surgery.

<< Previous
Dynamic Contrast-enhanced-magnetic Resonance Imaging Evaluation...

Next >>
The Use of Adjunctive Hemostatic Agents for Tubeless Percutaneous...

The Impact of Diabetes Type 2 in the Pathogenesis of Benign Prostatic Hyperplasia: A Review
Advances in Urology, 11/10/09 Relevance Score: 85%

Association of Codon 10 Polymorphism of the Transforming Growth Factor Beta 1 Gene with Prostate Cancer and Hyperplasia in an Iranian Population
Urologia Internationalis, 10/16/09 Relevance Score: 84%

Significant Complications following Minimally Invasive Office-Based Treatments for BPH: Experience from a Tertiary Care Center
Current Urology, 11/13/09 Relevance Score: 82%

Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia
Indian Journal of Urology, 10/05/09 Relevance Score: 82%

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Cochrane Reviews, 10/20/09 Relevance Score: 80%